# Effect of Yong Chong Cao Capsule on Outcomes in Patients With Mild to Severe COPD

> **NCT03745261** · PHASE3 · UNKNOWN · sponsor: **Henan University of Traditional Chinese Medicine** · enrollment: 240 (estimated)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** Salbutamol (Ventolin®)
- **DRUG:** Tiotropium Bromide (Spiriva®)
- **DRUG:** Salmeterol / fluticasone (Seretide®)
- **DRUG:** YCC capsule
- **DRUG:** BL capsule

## Key facts

- **NCT ID:** NCT03745261
- **Lead sponsor:** Henan University of Traditional Chinese Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-06-20
- **Primary completion:** 2019-12
- **Final completion:** 2020-06
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2018-11-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03745261

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03745261, "Effect of Yong Chong Cao Capsule on Outcomes in Patients With Mild to Severe COPD". Retrieved via AI Analytics 2026-06-27 from https://api.ai-analytics.org/clinical/NCT03745261. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*